 | • レポートコード：MRC2211A054 • 出版社/出版日：Persistence Market Research / 2022年9月 • レポート形態：英文、PDF、255ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートは、世界の腫瘍性骨軟化症（TIO）市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症の危機分析、需要分析・予測、治療種類別（医薬品・サプリメント、外科手術）分析、エンドユーザー別（病院、専門クリニック、その他）分析、診断別（ラボラトリー、骨密度測定）分析、地域別（アメリカ、カナダ、日本、ヨーロッパ、中国、メキシコ、韓国、インド、ブラジル、豪州）分析、競争分析、仮定、調査手法などを整理しております。本書では、Ultragenyx Pharmaceutical Inc.、Dishman Carbogen Amcis Ltd.、Teva Pharmaceuticals、Glenmark Pharmaceuticals、Wockhardt Ltd、FDC Limited、Lupin Pharmaceuticals、Zydus Cadila Healthcare Ltd.、Intas Pharmaceuticals Ltd、Macleods Pharmaceuticalsなどの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症の危機分析 ・需要分析・予測 ・世界の腫瘍性骨軟化症（TIO）市場規模：治療種類別 - 腫瘍性骨軟化症（TIO）医薬品・サプリメントの市場規模 - 腫瘍性骨軟化症（TIO）外科手術の市場規模 ・世界の腫瘍性骨軟化症（TIO）市場規模：エンドユーザー別 - 病院における市場規模 - 専門クリニックにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の腫瘍性骨軟化症（TIO）市場規模：診断別 - ラボラトリーの市場規模 - 骨密度測定の市場規模 ・世界の腫瘍性骨軟化症（TIO）市場規模：地域別 - アメリカの腫瘍性骨軟化症（TIO）市場規模 - カナダの腫瘍性骨軟化症（TIO）市場規模 - 日本の腫瘍性骨軟化症（TIO）市場規模 - ヨーロッパの腫瘍性骨軟化症（TIO）市場規模 - 中国の腫瘍性骨軟化症（TIO）市場規模 - メキシコの腫瘍性骨軟化症（TIO）市場規模 - 韓国の腫瘍性骨軟化症（TIO）市場規模 - インドの腫瘍性骨軟化症（TIO）市場規模 - ブラジルの腫瘍性骨軟化症（TIO）市場規模 - 豪州の腫瘍性骨軟化症（TIO）市場規模 ・競争分析 ・仮定 ・調査手法 |
Tumour-Induced Osteomalacia Market: Report Scope
The latest publication by Persistence Market Research on the global tumour-induced osteomalacia market evaluates the opportunities and current market landscape, provides detailed analysis, and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for tumour-induced osteomalacia products and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the tumour-induced osteomalacia market. Shareholders in the tumour-induced osteomalacia market, industry experts, investors, researchers, and reporters, as well as business enthusiasts, can leverage insights and information presented in this Persistence Market Research study.
Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the tumour-induced osteomalacia market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the tumour-induced osteomalacia market offers information divided into four important segments – treatment, diagnosis, end user, and country. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Treatment
Drugs and Supplements
Burosumab -twza
Cinarcalcet
Calcium
Active Vitamin D (Calcitriol/α-calcitriol)
Phosphorus
Surgery
Diagnosis
Laboratories
Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
Serum Calcium, PTH, Vitamin D
Hyperphosphaturia (Secondary Effects of FDF-23)
Hypophosphatemia (Secondary Effects of FDF-23)
Bone Scans
Magnetic Resonance Imaging (MRI)
Computed Tomography (CT Scans)
Differential Diagnosis
Vitamin D Metabolism and Deficiency
Osteoporosis
Renal Osteodystrophy
Others
End User
Hospitals
Specialty Clinics
Others
Country
U.S.
Canada
Japan
European Countries
China
Mexico
South Korea
India
Brazil
Australia
Key Questions Answered in Report
Which countries will continue to remain the most profitable markets for tumour-induced osteomalacia over the coming years?
How will changing trends influence the market?
How has the COVID-19 crisis affected market growth?
How can market players capture the low-hanging opportunities in developed countries?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will influence the market?
How can companies in the tumour-induced osteomalacia market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the tumour-induced osteomalacia market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the tumour-induced osteomalacia market are more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand side & Supply Side trends
1.3. Analysis and Recommendations
2. Market Overview
2.1. Market Definition and Introduction
2.2. Market Taxonomy/ Research Scope
2.3. Inclusion Exclusion
3. Key Market Trends
3.1. Key Trends Influencing the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Introduction
4.1.1. Disease Epidemiology
4.1.2. Symptoms
4.1.3. Etiology and Pathophysiology
4.1.4. Prognosis
4.1.5. Key Unmet Needs
4.2. Regulatory Scenario
4.3. Product Adoption/ Usage Analysis
4.4. Clinical Trials
4.5. Key Promotional Strategies by Manufacturer
4.6. Recent Drug Approvals
4.7. Porter’s Analysis
4.8. PESTLE Analysis
5. Market Background
5.1. Macro-economic Factors
5.2. Forecast Factors – Relevance and Impact
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity
6. COVID 19 Impact Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis on Market Segments
7. Global Tumour-Induced Osteomalacia Market (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) and Analysis by Treatment Type, 2017-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Treatment Type, 2022-2032
8.3.1. Drugs and Supplements
8.3.1.1. Burosumab-twza
8.3.1.2. Cinarcalcet
8.3.1.3. Calcium
8.3.1.4. Active Vitamin D (Calcitriol/α-calcitriol)
8.3.1.5. Phosphorus
8.3.2. Surgery
8.4. Market Attractiveness Analysis by Treatment Type
9. Global Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032, by End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis by End User, 2017-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by End User, 2022-2032
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Others
9.4. Market Attractiveness Analysis by End User
10. Global Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Analysis by Diagnosis, 2017-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Diagnosis, 2022-2032
10.3.1. Laboratories
10.3.1.1. Elevated blood Fibroblast growth factor 23 (FGF-23)
10.3.1.2. Serum calcium, PTH, vitamin D
10.3.1.3. Hyperphosphaturia (Secondary effects of the FDF-23)
10.3.1.4. Hypophosphatemia (Secondary effects of the FDF-23)
10.3.2. Bone Scan
10.3.2.1. Magnetic Resonance Imaging (MRI)
10.3.2.2. Computed Tomography (CT scan)
10.3.3. Differential Diagnosis
10.3.3.1. Vitamin D metabolism and deficiency
10.3.3.2. Osteoporosis
10.3.3.3. Renal Osteodystrophy
10.3.3.4. Others
10.4. Market Attractiveness Analysis by Diagnosis
11. Global Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032, by Country
11.1. Introduction
11.1.1. Diagnosis
11.1.2. Country
11.1.3. Market Attractiveness Analysis
12. U.S. Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2017-2021
12.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
12.3.1. Treatment
12.3.1.1. by Treatment Type
12.3.1.2. by End User
12.3.2. Diagnosis
12.4. Market Attractiveness Analysis
13. Canada Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2017-2021
13.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
13.3.1. Treatment
13.3.1.1. by Treatment Type
13.3.1.2. by End User
13.3.2. Diagnosis
14. Japan Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2017-2021
14.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
14.3.1. Treatment
14.3.1.1. by Treatment Type
14.3.1.2. by End User
14.3.2. Diagnosis
14.4. Market Attractiveness Analysis
15. European Countries Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2017-2021
15.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
15.3.1. Treatment
15.3.1.1. by Treatment Type
15.3.1.2. by End User
15.3.2. Diagnosis
15.3.3. by End User
15.4. Market Attractiveness Analysis
16. China Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2017-2021
16.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
16.3.1. Treatment
16.3.1.1. by Treatment Type
16.3.1.2. by End User
16.3.2. Diagnosis
16.4. Market Attractiveness Analysis
17. Mexico Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2017-2021
17.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
17.3.1. Treatment
17.3.1.1. by Treatment Type
17.3.1.2. by End User
17.3.2. Diagnosis
17.4. Market Attractiveness Analysis
18. South Korea Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2017-2021
18.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
18.3.1. Treatment
18.3.1.1. by Treatment Type
18.3.1.2. by End User
18.3.2. Diagnosis
18.4. Market Attractiveness Analysis
19. India Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2017-2021
19.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
19.3.1. Treatment
19.3.1.1. by Treatment Type
19.3.1.2. by End User
19.3.2. Diagnosis
19.4. Market Attractiveness Analysis
20. Brazil Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
20.1. Introduction
20.2. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2017-2021
20.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
20.3.1. Treatment
20.3.1.1. by Treatment Type
20.3.1.2. by End User
20.3.2. Diagnosis
20.4. Market Attractiveness Analysis
21. Australia Tumour-Induced Osteomalacia Market Analysis 2017-2021 and Forecast 2022-2032
21.1. Introduction
21.2. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2017-2021
21.3. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022-2032
21.3.1. Treatment
21.3.1.1. by Treatment Type
21.3.1.2. by End User
21.3.2. Diagnosis
21.4. Market Attractiveness Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive
22.3.1. Ultragenyx Pharmaceutical Inc.
22.3.1.1. Overview
22.3.1.2. Hormone Portfolio
22.3.1.3. Key Financial
22.3.1.4. Sales Footprint
22.3.1.5. Strategy Overview
22.3.1.6. SWOT Analysis
22.3.2. Dishman Carbogen Amcis Ltd.
22.3.2.1. Overview
22.3.2.2. Hormone Portfolio
22.3.2.3. Key Financial
22.3.2.4. Sales Footprint
22.3.2.5. Strategy Overview
22.3.2.6. SWOT Analysis
22.3.3. Teva Pharmaceuticals
22.3.3.1. Overview
22.3.3.2. Hormone Portfolio
22.3.3.3. Key Financial
22.3.3.4. Sales Footprint
22.3.3.5. Strategy Overview
22.3.3.6. SWOT Analysis
22.3.4. Glenmark Pharmaceuticals
22.3.4.1. Overview
22.3.4.2. Hormone Portfolio
22.3.4.3. Key Financial
22.3.4.4. Sales Footprint
22.3.4.5. Strategy Overview
22.3.4.6. SWOT Analysis
22.3.5. Wockhardt Ltd
22.3.5.1. Overview
22.3.5.2. Hormone Portfolio
22.3.5.3. Key Financial
22.3.5.4. Sales Footprint
22.3.5.5. Strategy Overview
22.3.5.6. SWOT Analysis
22.3.6. FDC Limited
22.3.6.1. Overview
22.3.6.2. Hormone Portfolio
22.3.6.3. Key Financial
22.3.6.4. Sales Footprint
22.3.6.5. Strategy Overview
22.3.6.6. SWOT Analysis
22.3.7. Lupin Pharmaceuticals
22.3.7.1. Overview
22.3.7.2. Hormone Portfolio
22.3.7.3. Key Financial
22.3.7.4. Sales Footprint
22.3.7.5. Strategy Overview
22.3.7.6. SWOT Analysis
22.3.8. Zydus Cadila Healthcare Ltd.
22.3.8.1. Overview
22.3.8.2. Hormone Portfolio
22.3.8.3. Key Financial
22.3.8.4. Sales Footprint
22.3.8.5. Strategy Overview
22.3.8.6. SWOT Analysis
22.3.9. Intas Pharmaceuticals Ltd
22.3.9.1. Overview
22.3.9.2. Hormone Portfolio
22.3.9.3. Key Financial
22.3.9.4. Sales Footprint
22.3.9.5. Strategy Overview
22.3.9.6. SWOT Analysis
22.3.10. Macleods Pharmaceuticals
22.3.10.1. Overview
22.3.10.2. Hormone Portfolio
22.3.10.3. Key Financial
22.3.10.4. Sales Footprint
22.3.10.5. Strategy Overview
22.3.10.6. SWOT Analysis
22.3.11. G.C. Chemie Pharmie Ltd
22.3.11.1. Overview
22.3.11.2. Hormone Portfolio
22.3.11.3. Key Financial
22.3.11.4. Sales Footprint
22.3.11.5. Strategy Overview
22.3.11.6. SWOT Analysis
22.3.12. Santiago Life Sciences
22.3.12.1. Overview
22.3.12.2. Hormone Portfolio
22.3.12.3. Key Financial
22.3.12.4. Sales Footprint
22.3.12.5. Strategy Overview
22.3.12.6. SWOT Analysis
23. Assumptions and Acronyms Used
24. Research Methodology
Table 01: Global Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment TypeTable 02: Global Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 03: Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Country
Table 04: Global Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 05: Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Country
Table 06: U.S Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 07: U.S Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 08: U.S Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 09: Canada Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 10: Canada Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 11: Canada Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 12: Japan Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 13: Japan Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 14: Japan Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 15: European Countries Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 16: European Countries Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 17: European Countries Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 18: China Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 19: China Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 20: China Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 21: Mexico Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 22: Mexico Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 23: Mexico Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 24: South Korea Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 25: South Korea Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 26: South Korea Tumour-Induced Osteomalacia Market [Diagnosis] Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 27: India Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 28: India Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 29: India Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 30: Brazil Tumour-Induced Osteomalacia Market [Treatment] Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 31: Brazil Tumour-Induced Osteomalacia Market [Treatment] Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 32: Brazil Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis
Table 33: Australia Tumour-Induced Osteomalacia Market [Treatment Type] Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Treatment Type
Table 34: Australia Tumour-Induced Osteomalacia Market [Treatment Type] Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 35: Australia Tumour-Induced Osteomalacia Market Value (US$ Thousands) Analysis 2017-2021 and Forecast 2022-2032, by Diagnosis